Literature DB >> 7822022

Immunization with live recombinant Salmonella typhimurium aroA producing F1 antigen protects against plague.

P C Oyston1, E D Williamson, S E Leary, S M Eley, K F Griffin, R W Titball.   

Abstract

An attenuated Salmonella typhimurium strain which expressed the F1 capsular antigen of Yersinia pestis was constructed by transformation of S. typhimurium SL3261 with plasmid pFGAL2a, a derivative of pUC18 which contained the caf1 gene without the leader sequence. The recombinant was used to vaccinate mice intragastrically and intravenously. The immunity induced was able to protect mice against challenge with a virulent strain of plague. Protection correlated with the induction of high titers of immunoglobulin G in serum samples and a specific T-cell response.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7822022      PMCID: PMC173032          DOI: 10.1128/iai.63.2.563-568.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

Review 1.  Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens.

Authors:  L Cárdenas; J D Clements
Journal:  Clin Microbiol Rev       Date:  1992-07       Impact factor: 26.132

2.  Genetic analysis of the 9.5-kilobase virulence plasmid of Yersinia pestis.

Authors:  O A Sodeinde; J D Goguen
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

3.  Characterization of aromatic- and purine-dependent Salmonella typhimurium: attention, persistence, and ability to induce protective immunity in BALB/c mice.

Authors:  D O'Callaghan; D Maskell; F Y Liew; C S Easmon; G Dougan
Journal:  Infect Immun       Date:  1988-02       Impact factor: 3.441

Review 4.  Plague immunization. I. Past and present trends.

Authors:  K F Meyer; D C Cavanaugh; P J Bartelloni; J D Marshall
Journal:  J Infect Dis       Date:  1974-05       Impact factor: 5.226

5.  Immunogenicity of a candidate live oral typhoid/cholera hybrid vaccine in humans.

Authors:  B D Forrest; J T LaBrooy; S R Attridge; G Boehm; L Beyer; R Morona; D J Shearman; D Rowley
Journal:  J Infect Dis       Date:  1989-01       Impact factor: 5.226

6.  Recombinant capsular antigen (fraction 1) from Yersinia pestis induces a protective antibody response in BALB/c mice.

Authors:  W J Simpson; R E Thomas; T G Schwan
Journal:  Am J Trop Med Hyg       Date:  1990-10       Impact factor: 2.345

7.  Molecular genetic analysis of beta-toxin of Clostridium perfringens reveals sequence homology with alpha-toxin, gamma-toxin, and leukocidin of Staphylococcus aureus.

Authors:  S E Hunter; J E Brown; P C Oyston; J Sakurai; R W Titball
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

Review 8.  The low-Ca2+ response virulence regulon of human-pathogenic Yersiniae.

Authors:  S C Straley
Journal:  Microb Pathog       Date:  1991-02       Impact factor: 3.738

9.  Application of enzyme immunoassays for the confirmation of clinically suspect plague in Namibia, 1982.

Authors:  J E Williams; L Arntzen; G L Tyndal; M Isaäcson
Journal:  Bull World Health Organ       Date:  1986       Impact factor: 9.408

10.  The route of enteric infection in normal mice.

Authors:  P B Carter; F M Collins
Journal:  J Exp Med       Date:  1974-05-01       Impact factor: 14.307

View more
  18 in total

1.  Yersinia pestis pFra shows biovar-specific differences and recent common ancestry with a Salmonella enterica serovar Typhi plasmid.

Authors:  M B Prentice; K D James; J Parkhill; S G Baker; K Stevens; M N Simmonds; K L Mungall; C Churcher; P C Oyston; R W Titball; B W Wren; J Wain; D Pickard; T T Hien; J J Farrar; G Dougan
Journal:  J Bacteriol       Date:  2001-04       Impact factor: 3.490

Review 2.  Developing live vaccines against plague.

Authors:  Wei Sun; Kenneth L Roland; Roy Curtiss
Journal:  J Infect Dev Ctries       Date:  2011-09-14       Impact factor: 0.968

3.  Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge.

Authors:  G P Andrews; D G Heath; G W Anderson; S L Welkos; A M Friedlander
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

4.  Oral administration of a recombinant attenuated Yersinia pseudotuberculosis strain elicits protective immunity against plague.

Authors:  Wei Sun; Shilpa Sanapala; Hannah Rahav; Roy Curtiss
Journal:  Vaccine       Date:  2015-10-26       Impact factor: 3.641

5.  Antibiotic-free plasmid stabilization by operator-repressor titration for vaccine delivery by using live Salmonella enterica Serovar typhimurium.

Authors:  Helen S Garmory; Matthew W Leckenby; Kate F Griffin; Stephen J Elvin; Rosa R Taylor; M Gill Hartley; Julian A J Hanak; E Diane Williamson; Rocky M Cranenburgh
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

6.  Yersinia pestis V protein epitopes recognized by CD4 T cells.

Authors:  Michelle A Parent; Kiera N Berggren; Isis K Mullarky; Frank M Szaba; Lawrence W Kummer; Jeffrey J Adamovicz; Stephen T Smiley
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

7.  Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization.

Authors:  J Hill; S E Leary; K F Griffin; E D Williamson; R W Titball
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

8.  Oral vaccination against bubonic plague using a live avirulent Yersinia pseudotuberculosis strain.

Authors:  Thierry Blisnick; Patrick Ave; Michel Huerre; Elisabeth Carniel; Christian E Demeure
Journal:  Infect Immun       Date:  2008-05-27       Impact factor: 3.441

Review 9.  Immune defense against pneumonic plague.

Authors:  Stephen T Smiley
Journal:  Immunol Rev       Date:  2008-10       Impact factor: 12.988

10.  Mucosally delivered Salmonella typhi expressing the Yersinia pestis F1 antigen elicits mucosal and systemic immunity early in life and primes the neonatal immune system for a vigorous anamnestic response to parenteral F1 boost.

Authors:  Karina Ramirez; Alejandra V E Capozzo; Scott A Lloyd; Marcelo B Sztein; James P Nataro; Marcela F Pasetti
Journal:  J Immunol       Date:  2009-01-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.